Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
- Resource Type
- Article
- Authors
- Laribi, Kamel; Poulain, Stéphanie; Willems, Lise; Merabet, Fatiha; Herbaux, Charles; Roos‐Weil, Damien; Laribi de Materre, Inès; Roussel, Xavier; Nudel, Morgane; Tricot, Sabine; Dupuis, Jehan; Le Calloch, Ronan; Bareau, Benoit; Leblond, Véronique
- Source
- British Journal of Haematology. Jun2024, Vol. 204 Issue 6, p2233-2236. 4p.
- Subject
- *RITUXIMAB
*LEUKEMIA
*OVERALL survival
*CONFIDENCE intervals
*THERAPEUTICS
- Language
- ISSN
- 0007-1048
Summary: The bendamustine–rituximab (BR) schedule is an efficient first‐line therapy in Waldenström macroglobulinaemia (WM). A previous analysis of 69 patients who received this treatment confirmed a high response rate and good progression‐free (PFS) and overall survival (OS). With a median follow‐up of 76.1 months (95% confidence interval [CI] 69.9–80.6), 5‐year outcome is still excellent at 66.63% (95% CI 56.09–79.17) for PFS and 80.01% (95% CI 70.82–90.41) for OS. The rate of secondary cancers is 17.66% (IQR 7.99–27.64) at 66 months. Relapsed patients who received ibrutinib as second‐line clearly benefited from this schedule. This confirms current recommendations suggesting BR long‐term efficacy as first‐line option in WM. [ABSTRACT FROM AUTHOR]